Immunological aspects of COVID-19 in children
https://doi.org/10.31146/2949-4664-apps-2-1-96-103
Abstract
About the Authors
A. V. VolkovRussian Federation
T. A. Ruzhentsova
Russian Federation
References
1. Yuki К.,Fujiogi М., Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol. 2020; 215: 108427. doi: 10.1016/j.clim.2020.108427
2. Wu Z., McGoogan J. M. Characteristics of and important lessons from the Coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13): 1239-1242. doi: 10.1001/jama.2020.2648.
3. Dong Y., Mo X., Hu Y. et al. Epidemiology of COVID-19 Among Children in China. Pediatrics. 2020;145(6): e20200702. doi: 10.1542/peds.2020-0702.
4. Livingston E., Bucher K. Coronavirus disease 2019 (COVID-19) in Italy. JAMA. 2020; 323(14): 1335. doi: 10.1001/jama.2020.4344.
5. Furman E. G. Coronavirus infection COVID-19 and children. Pediatria n. a. G. N. Speransky. 2020; 99 (3): 245-251. (In Russ.) doi: 10.24110/0031-403X-2020-99-3-245-251.@@ Фурман Е. Г. Коронавирусная инфекция COVID-19 и дети. Педиатрия им. Г. Н. Сперанского. 2020; 99 (3): 245-251. doi: 10.24110/0031-403X-2020-99-3-245-251.
6. Valentini B., Sodero G., Buonsenso D. The Relationship between COVID-19 and Innate Immunity in Children: A Review. Children. 2021; 8(4): 266. doi: 10.3390/children8040266.
7. Bitar R. R., Alattas B., Azaz A. et al. Gastrointestinal manifestations in children with COVID-19 infection: Retrospective tertiary center experience. Front Pediatr. 2022; 10: 925520. doi: 10.3389/fped.2022.925520.
8. Gorelov A. V., Nikolaeva S. V., Usenko D. V. et al. The effectiveness of using nifuroxazide in acute intestinal infections of bacterial etiology in children. Infekc. bolezni (Infectious diseases). 2018; 16(2): 18-26. (In Russ.) doi: 10.20953/1729-9225-2018-2-18-26.@@ Горелов А. В., Николаева С. В., Усенко Д. В. и др. Эффективность применения нифуроксазида при острых кишечных инфекциях бактериальной этиологии у детей. Инфекционные болезни. 2018; 16(2): 18-26. doi: 10.20953/1729-9225-2018-2-18-26.
9. Ruzhentsova T. A., Ploskireva A. A., Milutina L. N., Gorelov A. V. Features of the use of antibacterial therapy in children with acute intestinal infections. Meditsinskiy Sovet. 2016; 1: 98-101. (In Russ.)@@ Руженцова Т. А., Плоскирева А. А., Милютина Л. Н., Горелов А. В. Особенности применения антибактериальной терапии у детей при острых кишечных инфекциях. Медицинский совет. 2016; 1: 98-101.
10. Ruzhentsova T. A., Ploskireva A. A., Gorelov A. V. Acute diarrhea of bacterial etiology: differential diagnosis and treatment. Meditsinskiy Sovet. 2016; 7: 78-81. (In Russ.) doi: 10.21518/2079-701X-2016-07-78-81.@@ Руженцова Т. А., Плоскирева А. А., Горелов А. В. Острая диарея бактериальной этиологии: дифференциальная диагностика и лечение. Медицинский совет. 2016; 7: 78-81. doi: 10.21518/2079-701X-2016-07-78-81.
11. Sharif-Askari N.S., Sharif-Askari F.S., Alabed M. et al. Airways Expression of SARS-CoV-2 Receptor, ACE2, and TMPRSS2 Is Lower in Children Than Adults and Increases with Smoking and COPD. Mol Ther Methods Clin Dev. 2020; 18: 1-6. doi: 10.1016/j.omtm.2020.05.013.
12. Alabsi S., Dhole A., HozayenS. et al. Angiotensin-Converting Enzyme 2 Expression and Severity of SARS-CoV-2 Infection. Microorganisms. 2023; 11(3): 612. doi: 10.3390/microorganisms11030612.
13. Jia H. P., Look D. C., Shi L. et al. ACE2 Receptor Expression and Severe Acute Respiratory Syndrome Coronavirus Infection Depend on Differentiation of Human Airway Epithelia. Journal of Virology. 2005; 79(23): 14614-14621. doi: 10.1128/jvi.79.23.14614-14621.2005.
14. Sposato B., Scalese M. Why do children seem to be more protected against COVID-19? A hypothesis. Med Hypotheses. 2020; 143: 110151. doi: 10.1016/j.mehy.2020.110151.
15. Schurink B., Roos E., Vos W. et al. ACE2 Protein Expression During Childhood, Adolescence, and Early Adulthood. Pediatr Dev Pathol. 2022; 25(4): 404-408. doi: 10.1177/10935266221075312.
16. Collier F., ChauC., Mansell T. et al. Innate Immune Activation and Circulating Inflammatory Markers in Preschool Children. Front Immunol. 2022; 12: 830049. doi: 10.3389/fimmu.2021.830049.
17. Pierce C. A., Sy S., Galen B. et al. Natural Mucosal Barriers and COVID-19 in Children. MedRxiv. 2021: 2021.02.12.21251310. doi: 10.1101/2021.02.12.21251310.
18. Furman E. G., Khuzina E. A., Repetskaya M. N. Bronchial Asthma in Children Amidst the Novel Coronavirus Infection. Doctor.Ru. 2020; 19(10): 42-47. (In Russ.) doi: 10.31550/1727-2378-2020-19-10-42-47.@@ Фурман Е. Г., Хузина Е. А., Репецкая М. Н. Бронхиальная астма у детей в условиях новой коронавирусной инфекции. Доктор.Ру. 2020; 19(10): 42-47. doi: 10.31550/1727-2378-2020-19-10-42-47.
19. Novikova Yu. Yu., Ovsyannikov D. Yu., Glazyrina A. A. et al. Multisystem inflammatory syndrome in children associated with COVID-19: results of a multicenter study. Pediatria n. a. G. N. Speransky. 2021; 100 (6): 23-31. (In Russ.) doi: 10.24110/0031-403X-2021-100-6-23-31.@@ Новикова Ю. Ю., Овсянников Д. Ю., Глазырина А. А. и др. Детский мультисистемный воспалительный синдром, ассоциированный с новой коронавирусной инфекцией COVID-19: результаты многоцентрового исследования. Педиатрия им. Г. Н. Сперанского. 2021; 100 (6): 23-31. doi: 10.24110/0031-403X-2021-100-6-23-31.
20. Rostad C. A., Chahroudi A., Mantus G. et al, Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C). Pediatrics. 2020; 146(6): e2020018242. doi: 10.1542/peds.2020-018242.
21. Pfeifer J., Thurner B., Kessel C. et al. Autoantibodies against interleukin-1 receptor antagonist in multisystem inflammatory syndrome in children: a multicentre, retrospective, cohort study. Lancet Rheumatol. 2022; 4(5): e329-e337. doi: 10.1016/S2665-9913(22)00064-9.
22. Jain E., Donowitz J. R., Aarons E. et al. Multisystem Inflammatory Syndrome in Children after SARS-CoV-2 Vaccination. Emerg Infect Dis. 2022; 28(5): 990-993. doi: 10.3201/eid2805.212418.
23. Yousaf A. R., Cortese M. M., Taylor A. W. et al. Reported cases of multisystem inflammatory syndrome in children aged 12-20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigation. Lancet Child Adolesc Health. 2022; 6(5): 303-312. doi: 10.1016/S2352-4642(22)00028-1.
24. Filippatos F., Tatsi E.-B., Michos A. Innate Immune Activation and Circulating Inflammatory Markers in Preschool Children.Int J Mol Sci. 2023; 24(6): 5711. doi: 10.3390/ijms24065711.
Review
For citations:
Volkov A.V., Ruzhentsova T.A. Immunological aspects of COVID-19 in children. Archives of Pediatrics and Pediatric Surgery. 2024;2(1):96-103. (In Russ.) https://doi.org/10.31146/2949-4664-apps-2-1-96-103